Design Therapeutics, Inc. reports news about its clinical-stage biotechnology business and its GeneTAC® platform for serious degenerative genetic diseases. The company develops gene targeted chimera small molecules designed to modulate expression of disease-causing genes, with programs that include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type 1, and a Huntington’s disease program.
Recurring updates cover financial results, cash resources for pipeline execution, clinical program progress, regulatory clearances, preclinical development, investor conference participation, and board or committee changes. Company announcements frequently connect portfolio milestones with the underlying GeneTAC approach and the therapeutic areas addressed by its genomic medicine programs.
Design Therapeutics (NASDAQ: DSGN) reported Q1 2026 results and program updates on April 28, 2026. The company closed the quarter with $222.8 million in cash, cash equivalents and investment securities, supporting operations into 2029. Q1 spending included $14.4M R&D and $5.3M G&A, with a $17.6M net loss. Clinical progress: ongoing RESTORE-FA multiple-ascending-dose trial of DT-216P2 with frataxin biomarker readout expected in H2 2026; Phase 2 DT-168 FECD biomarker data also expected H2 2026; dosing for DT-818 (DM1) anticipated H1 2026. David Shapiro, M.D., joined the board to support clinical and regulatory strategy.
Design Therapeutics (Nasdaq: DSGN) reported fourth-quarter and full-year 2025 results and updates on its GeneTAC® clinical portfolio. Cash, cash equivalents and investment securities were $219.8 million as of December 31, 2025, which the company expects to fund operations into 2029. Three programs are advancing: DT-216P2 (FA) and DT-168 (FECD) with data anticipated in H2 2026, and DT-818 (DM1) with patient dosing planned in H1 2026. 2025 expenses included R&D of $59.1 million and net loss of $69.8 million.
Design Therapeutics (Nasdaq: DSGN) will present at two investor conferences in early 2026: Oppenheimer 36th Annual Healthcare Life Sciences on Feb 25, 2026 at 1:20 PM ET (virtual) and Leerink Partners Global Healthcare on Mar 10, 2026 at 2:20 PM ET in Miami.
Live webcasts will be available on the company’s investor website and archived for at least 30 days after each presentation.
Design Therapeutics (Nasdaq: DSGN) announced management will participate in two investor fireside chats in early December 2025: Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 3:30 p.m. ET in New York and Evercore 8th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:00 a.m. ET in Coral Gables, Florida.
Live webcasts will be available on the company’s investor site at www.designtx.com and will be archived for at least 30 days after each presentation.
Design Therapeutics (NASDAQ: DSGN) announced nomination of DT-818 as its development candidate for myotonic dystrophy type-1 (DM1) and obtained ex‑US regulatory clearance to start clinical development. The company plans a Phase 1 multiple-ascending dose trial in Australia with patient dosing to begin in the first half of 2026 and splicing data expected in 2027. Design continues dosing in its RESTORE-FA trial of DT-216P2 and an ongoing Phase 2 biomarker trial of DT-168, both with data anticipated in the second half of 2026. Preclinical DT-818 showed >90% reduction in toxic RNA foci and selective targeting of mutant DMPK. Cash, cash equivalents and investment securities totaled $206.0 million as of September 30, 2025, with a reported Q3 2025 net loss of $17.0 million.
Design Therapeutics (Nasdaq: DSGN), a clinical-stage biotech company, has appointed Justin Gover to its Board of Directors. Gover brings over 25 years of biotech leadership experience, notably as the founding CEO of GW Pharmaceuticals, which he led to a $7 billion acquisition by Jazz Pharmaceuticals in 2021.
The appointment comes as Dr. Arsani William steps down from the Board. William, who joined in 2021, helped guide Design through its IPO and clinical pipeline advancement. Gover currently serves on the boards of Compass Pathways and Xenon Pharmaceuticals, bringing valuable experience in transforming innovative science into commercial medicines.
Design Therapeutics (NASDAQ:DSGN), a clinical-stage biotech company focused on developing treatments for degenerative genetic diseases, has announced its participation in the upcoming 2025 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on September 4, 2025, at 10:55 a.m. ET in New York.
Investors can access the presentation through a live webcast available on the company's website, which will remain archived for at least 30 days after the event.
Design Therapeutics (NASDAQ:DSGN) reported progress in its GeneTAC® programs and Q2 2025 financial results. The company announced encouraging early pharmacokinetics data for DT-216P2 in Friedreich Ataxia (FA), showing favorable translation from non-human primates to humans via both intravenous and subcutaneous administration.
Key developments include the ongoing RESTORE-FA Phase 1/2 trial of DT-216P2 outside the US, while addressing an FDA clinical hold notice. The company also initiated a Phase 2 biomarker trial for DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) patients. Design reported $216.3 million in cash and securities, with a Q2 net loss of $19.1 million.
[ "Favorable pharmacokinetics data translation from non-human primates to humans for DT-216P2", "DT-216P2 showed improved exposure and PK parameters compared to previous formulation", "Strong cash position of $216.3 million to support pipeline development", "Advancement of multiple clinical programs including FA and FECD treatments" ]Design Therapeutics (NASDAQ: DSGN), a clinical-stage biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York. Interested parties can access a live webcast of the presentation through the company's website or the provided link, with the recording remaining available for at least 30 days after the event.